Navigation Links
Trevena Appoints Roberto Cuca as Senior Vice President & Chief Financial Officer
Date:9/17/2013

KING OF PRUSSIA, Pa., Sept. 17, 2013 /PRNewswire/ -- Trevena, Inc., (Trevena) a clinical stage pharmaceutical company and a leader in the discovery and development of G-protein coupled receptor (GPCR) biased ligands, today announced the appointment of Roberto Cuca as senior vice president and chief financial officer.

"We are delighted to have Roberto join Trevena at this pivotal juncture in the company's development," said Maxine Gowen, Ph.D., president and chief executive officer of Trevena. "Roberto's diverse experience in effectively transitioning both private and public healthcare companies through phases of rapid growth will be invaluable in assisting Trevena through its corporate and strategic evolution."

Mr. Cuca brings to Trevena nearly 20 years of experience in the pharmaceutical and biotechnology industries. Most recently, he served as Treasurer and Senior Vice President, Finance at Endo Health Solutions Inc., a specialty healthcare company. Before that, he was Director, Corporate and Business Development, at moksha8 Pharmaceuticals, Inc., a pharmaceutical company focused on emerging markets. Mr. Cuca also worked at JPMorgan Chase & Co. as an equity analyst covering U.S. pharmaceutical companies. He received an M.B.A. from the Wharton School of The University of Pennsylvania, a J.D. from Cornell Law School, an A.B. from Princeton University and he is a CFA charterholder.

"I am excited to join Trevena and work with its exceptional team at a time of such great promise," said Mr. Cuca. "The company has made significant progress in advancing its compounds into the clinic, collaborating with world-class global pharmaceutical companies and successfully securing financing to support the development of its clinical programs.  I look forward to helping the company progress towards its next phase of development."

About Biased Ligands'/>"/>

SOURCE Trevena, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Trevena, Inc. to Present at the 12th Annual Needham Healthcare Conference
2. Trevena, Inc. and Forest Laboratories Announce a Collaborative Agreement For Development of TRV027 for the Treatment of Acute Heart Failure
3. Trevena Granted Key Composition of Matter Patent for TRV027 in U.S.
4. Mechanism for Cardiac Effects of Trevena Angiotensin Receptor Biased Ligands Examined in Published Study
5. Winner Medicals Special Committee Appoints Independent Financial Advisor and Retains Legal Counsel
6. Pro-Dex, Inc. Appoints Michael J. Berthelot Chief Executive Officer
7. Nephros Appoints John C. Houghton as President and Chief Executive Officer
8. Elsevier Appoints New President of Elsevier CPM Resource Center
9. GenWay Biotech Appoints New Vice President of Custom/OEM
10. Angeion Appoints Matthew S. Margolies as Executive Vice President - Global Sales
11. Althea Technologies Appoints Dr. Kristin DeFife, Director, Biologics Manufacturing And Jack Wright, VP, Sales and Marketing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... Aug. 27, 2015 DURECT Corporation (Nasdaq: ... present at three upcoming healthcare conferences.  ... will present at the Rodman & Renshaw Investment Conference ... The conference is being held at the St. Regis ... A live audio webcast of the presentation will be ...
(Date:8/27/2015)... , Aug. 27, 2015 ieCrowd™ today ... the commercial development of the company,s supplemental oxygen ... Oxygen device, being developed by ieCrowd,s subsidiary Smart ... patient,s changing demand for oxygen based on level ... (k) submission for the Smart Oxygen device would ...
(Date:8/27/2015)... Lilly and Company (NYSE: LLY ) will attend ... 17, 2015. Sue Mahony , Ph.D., senior vice ... Gaynor , M.D., senior vice president of product development ... a fireside chat at 3:30 p.m., Eastern Daylight Time. ... available on the "Webcasts & Presentations" section of Lilly,s ...
Breaking Medicine Technology:DURECT to Participate in Upcoming Healthcare Conferences 2Smart Oxygen Solutions' Supplemental Oxygen Delivery Device Achieves FDA Regulatory Pathway Milestone 2Smart Oxygen Solutions' Supplemental Oxygen Delivery Device Achieves FDA Regulatory Pathway Milestone 3Smart Oxygen Solutions' Supplemental Oxygen Delivery Device Achieves FDA Regulatory Pathway Milestone 4Lilly to Participate in Morgan Stanley Global Healthcare Conference 2
... Be Useful in Cancer Treatment,Decisions , SALT LAKE ... (<a target="_blank" href=,"http://www.myriad.com/">www.myriad.com ) announced today that,it presented ... used to,determine the original location of a metastatic ... meeting of the American Association,for Cancer Research (AACR) ...
... WIRE)--Apr 19, 2007 - King,Pharmaceuticals, Inc. (NYSE:KG) ... results from the Phase III clinical trial,evaluating ... ALTACE(R),(ramipril) diuretic fixed-dose combination product. The Company ... expects to present the,findings in detail at ...
Cached Medicine Technology:Myriad Genetics Presents Tumor Origin Technology at AACR 2Myriad Genetics Presents Tumor Origin Technology at AACR 3King Pharmaceuticals Announces Plan to Report Positive Data from,Phase III Clinical Trial Evaluating the Combination of Altace with,Hydrochlorothiazide 2
(Date:8/28/2015)... ... ... Dr. Gregory K. Toumayan, D.C., Q.M.E., is now treating patients with back pain and ... neck pain, stiffness, muscle spasms, and numbness. , Dr. Toumayan received his Bachelor ... to earn his title of Doctor of Chiropractic from the Palmer College of Chiropractic ...
(Date:8/28/2015)... ... August 28, 2015 , ... The Quatela Center for ... is the first and only nonsurgical product approved by the Food and Drug Administration ... Quatela and Dr. William Koenig are among the premier cosmetic surgeons ...
(Date:8/28/2015)... ... 28, 2015 , ... Mendon, IL, home of the Adams County Fairgrounds, was ... for a good cause. In its second year, the “Music With A Mission” benefit ... Rehabilitation. The “Mission” of “Music With A Mission” is to raise money to help ...
(Date:8/28/2015)... , ... August 28, 2015 , ... ... evaluations for those seeking to go deep sea diving. The act of ... and decompression sickness; for these reasons, it is vital that all recreational and ...
(Date:8/28/2015)... ... August 28, 2015 , ... The newest therapy to receive orphan ... general use any time soon, according to educational website Surviving Mesothelioma. Click here ... orphan drug designation for mesothelioma last week from the FDA, will now head into ...
Breaking Medicine News(10 mins):Health News:Healthpointe Welcomes Dr. Gregory K. Toumayan, Chiropractor, to Colton, Temecula, and Perris 2Health News:Healthpointe Welcomes Dr. Gregory K. Toumayan, Chiropractor, to Colton, Temecula, and Perris 3Health News:Non-surgical Treatment to Get Rid of The "Double Chin," Kybella™, Now Available at the Quatela Center for Plastic Surgery 2Health News:Non-surgical Treatment to Get Rid of The "Double Chin," Kybella™, Now Available at the Quatela Center for Plastic Surgery 3Health News:Best Drug Rehabilitation Sponsors "Music With A Mission" Concert Featuring Avenue Beat 2Health News:Healthpointe Now Offering Scuba Physicals 2Health News:Surviving Mesothelioma Puts New Orphan Drug into Perspective in New Article 2
... VSCP ), a leading provider of quantitative ... exceeds $27 million,compared to $14.7 million at the same ... company calculates backlog as the amount remaining to be,recognized ... studies,included within the backlog ranges from 2 months to ...
... nationally recognized Consumer Watchdog sent a letter today to ... to make health care affordable and available by allowing ... group warned Obama that a proposal pushed by health ... health insurance policies "amounts only to a government-funded customer ...
... Costs as Key , , WASHINGTON, ... Excellence report looks at how states are balancing retiree health care ... , Retiree Health Care in the American States ... care benefits to central human resources (HR) goals; how the states ...
... Diagnostics Incorporated (NYSE: DGX ), the world,s leading ... is scheduled to speak at the Piper Jaffray Healthcare Conference ... Quest Diagnostics presentation is scheduled to begin at 4:00 p.m. ... During the conference, the company will reaffirm its 2008 ...
... Patients treated with radiation prior to surgery for ... and better overall survival rates, according to a recent ... neoadjuvant therapy, which can reduce cancerous tumor size or ... the tumor. Neoadjuvant therapy may include chemotherapy and/or radiation. ...
... probably higher with aprotinin, a drug commonly used to control ... analogues, according to a study http://www.cmaj.ca//cgi/rapidpdf/cmaj.081109 to be ... , On December 3, a Health Canada expert advisory ... is being early released in advance of the meeting. ...
Cached Medicine News:Health News:VirtualScopics Backlog Rises to a Record $27 Million 2Health News:VirtualScopics Backlog Rises to a Record $27 Million 3Health News:Consumer Watchdog to Obama: Open Medicare to All Americans 2Health News:Consumer Watchdog to Obama: Open Medicare to All Americans 3Health News:States View Limits on Retiree Health Benefits 2Health News:Quest Diagnostics to Speak at the 20th Annual Piper Jaffray Healthcare Conference 2
... automated, wireless, computerized remote temperature monitoring, ... refrigerator, freezer, incubator and water bath ... and manual temperature log reports., The ... and comes complete with installation, training ...
... water for use, it provides ... physically clean hands when routine ... an option or is not ... return to patient care faster, ...
BioSoft alcohol gel hand antiseptic with soothing moisturizers is a fast-acting, broad-spectrum antimicrobial solution. BioSoft alcohol gel hand antiseptic applies easily, requires no rinsing and dri...
Exidine® 2% CHG Brushless Surgical Scrub offers exceptional persistence and broad-spectrum antimicrobial activity....
Medicine Products: